It will be interesting to determine how neoplastic MYC, which does not remarkably require PARP activity in cisplatin-sensitive (i.e., early-stage) cancer cells, considerably depends on the PARP activity in cisplatin-resistant cancer cells. Here, MYC is linked to cancer.